Studying 23 FTY-treated MS patients, Song and colleagues15 found a higher frequency of CD4+ TCM in what they defined as ‘non-responders’ after 3–6 months of therapy, while the difference in TCM frequencies between our groups did not persist on-treatment (data not shown). This evidence concerns the gene CD4 and myeloid sarcoma.